0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Dengue Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

Dengue Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00 – $ 8,900.00

Dengue Vaccine Market: By Product Type (CYD-TDV (Dengvaxia), DENVax, TetraVax-DV, Others), By Vaccine Type (Live Attenuated Vaccine, Killed Vaccine, Others), By End User (Hospitals, Clinics, Government Institutes, Non-Governmental Organizations (NGOs)) and Geography

 

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,
Report

Description

Dengue Vaccine Market size was valued at USD 361 million in 2021. It is expected to reach a value of USD 1096.48 million by 2028, growing at a CAGR of 17.2% from 2022-28. As per the World Health Organization, the frequency of dengue has become significantly over ongoing many years. A larger part of the cases are asymptomatic, gentle or independent, and thus the genuine number of diseases are exceptionally under-announced. One displaying gauge demonstrates 390 million dengue infection diseases each year (95% valid span 284-528 million), of which 96 million show clinically. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, dengue vaccines market report covers newer product introductions and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the dengue vaccine market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of dengue vaccine.

Key Market Developments:

In May 2019, The Food and Drug Administration approved the first vaccine against dengue fever with major restrictions.

In May 2021, Takeda’s released Phase 3 results of Dengue Vaccine Candidate (TAK-003), which Prevented 83.6% of Hospitalizations and 62.0% of Dengue Illness Overall, With No Identified Important Safety Risks Through Three Years Following Vaccination in Ongoing Pivotal TIDES Trial.

Dengue Vaccine Market

MARKET SUMMARY
-
17.2% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 17.2%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– Latin America
Dengue Vaccine Market

  • The dengue vaccines market report gives a comprehensive outlook of dengue vaccine market across the globe with special emphasis on key regions such as Asia-Pacific, Latin America, and Middle East & Africa (MEA) North America, and Europe.
  • This report on global market gives historical, current, and future market sizes (US$ Mn) of product types, vaccine type, end users, and geographic regions.
Key Players
  • Sanofi (France)
  • Insitituto Butantan(Brazil)
  • Vabiotech (Vietnam)
  • Panacea Biotech(India)
  • GlaxoSmithKline plc (U.K)
  • Merck & Co. Inc. (U.S.)
Dengue Vaccine Market

Drivers and Restraints

Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by Aedes aegypti mosquito. Dengue fever is epidemic in several countries of Asia-pacific and Latin America region. The growing global epidemic of dengue in aforementioned regions is expected to create demand for the dengue vaccine over the forecast period. Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for dengue vaccine over the forecast period. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programmes to prevent the dengue epidemics. According to WHO estimates, there are around 50 Mn dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.

Dengue Vaccine Market Regional Analysis

Asia Pacific dominates the market

Asia-Pacific region expected to lead the global dengue vaccines market owing to widespread prevalence and incidence of dengue fever and large population, who are at dengue fever risk. Latin America expected to register highest market growth among all regions owing to the early adoption of the vaccine in government immunization programmes.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Dengue Vaccine Market Segmentation

segmentation-block-image

Product Type

    • CYD-TDV (Dengvaxia)
    • DENVax
    • TetraVax-DV
    • Others
segmentation-block-image

Vaccine Type

    • Live Attenuated Vaccine
    • Killed Vaccine
    • Others
segmentation-block-image

End Users

    • Hospitals
    • Clinics
    • Government Institutes
    • Non-Governmental Organization (NGOs)
segmentation-block-image

Geography

    • North America
    • Latin America
    • Europe
    • Asia Pacifc
    • MIddle East and Africa
Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Report

Table Of Content

1. Executive Summary
2. Global Dengue Vaccine Market Introduction
2.1. Global Dengue Vaccine Market – Taxonomy
2.2. Global Dengue Vaccine Market –Definitions
2.2.1. By Product Type
2.2.2. By Vaccine Type
2.2.3. By End User
2.2.4. By Region
3. Global Dengue Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dengue Vaccine Market Dynamic Factors – Impact Analysis
3.6. Global Dengue Vaccine Market – Competition Landscape
4. Global Dengue Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Dengue Vaccine Market, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. CYD-TDV (Dengvaxia)
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. DENVax
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. TetraVax-DV
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Dengue Vaccine Market, By Vaccine Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Live Attenuated Vaccine
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Killed Vaccine
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Dengue Vaccine Market Forecast, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. Hospitals
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Clinics
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Government Institutes
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Non-Governmental Organizations (NGOs)
7.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Dengue Vaccine Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Dengue Vaccine Market – Opportunity Analysis Index, By Product Type, By Application, By End User, and Region, 2022 – 2028
9. North America Dengue Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. CYD-TDV (Dengvaxia)
9.1.2. DENVax
9.1.3. TetraVax-DV
9.1.4. Others
9.2. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Live Attenuated Vaccine
9.2.2. Killed Vaccine
9.2.3. Others
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Government Institutes
9.3.4. Non-Governmental Organizations (NGOs)
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Dengue Vaccine Market – Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2022 – 2028
9.6. North America Dengue Vaccine Market Dynamics – Trends
10. Europe Dengue Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. CYD-TDV (Dengvaxia)
10.1.2. DENVax
10.1.3. TetraVax-DV
10.1.4. Others
10.2. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Live Attenuated Vaccine
10.2.2. Killed Vaccine
10.2.3. Others
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Government Institutes
10.3.4. Non-Governmental Organizations (NGOs)
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Benelux
10.4.8. Rest of Europe
10.5. Europe Dengue Vaccine Market – Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2022 – 2028
10.6. Europe Dengue Vaccine Market Dynamics – Trends
11. Asia-Pacific Dengue Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. CYD-TDV (Dengvaxia)
11.1.2. DENVax
11.1.3. TetraVax-DV
11.1.4. Others
11.2. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Live Attenuated Vaccine
11.2.2. Killed Vaccine
11.2.3. Others
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Government Institutes
11.3.4. Non-Governmental Organizations (NGOs)
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Dengue Vaccine Market – Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2022 – 2028
11.6. Asia-Pacific Dengue Vaccine Market Dynamics – Trends
12. Latin America Dengue Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. CYD-TDV (Dengvaxia)
12.1.2. DENVax
12.1.3. TetraVax-DV
12.1.4. Others
12.2. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Live Attenuated Vaccine
12.2.2. Killed Vaccine
12.2.3. Others
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Government Institutes
12.3.4. Non-Governmental Organizations (NGOs)
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Dengue Vaccine Market – Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2022 – 2028
12.6. Latin America Dengue Vaccine Market Dynamics – Trends
13. Middle East and Africa Dengue Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. CYD-TDV (Dengvaxia)
13.1.2. DENVax
13.1.3. TetraVax-DV
13.1.4. Others
13.2. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Live Attenuated Vaccine
13.2.2. Killed Vaccine
13.2.3. Others
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Government Institutes
13.3.4. Non-Governmental Organizations (NGOs)
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Dengue Vaccine Market – Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2022 – 2028
13.6. MEA Dengue Vaccine Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Takeda Pharmaceutical Company Limited
14.2.2. Serum Institute of India Pvt. Ltd
14.2.3. Panacea Biotec Limited
14.2.4. Sanofi Pasteur Limited
14.2.5. GeneOne Life Science
14.2.6. Sun Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms
Report

Company Profile

  • Takeda Pharmaceutical Company Limited
  • Serum Institute of India Pvt. Ltd
  • Panacea Biotec Limited
  • Sanofi Pasteur Limited
  • GeneOne Life Science
  • Sun Pharmaceutical Industries Ltd.

Description

Dengue Vaccine Market size was valued at USD 361 million in 2021. It is expected to reach a value of USD 1096.48 million by 2028, growing at a CAGR of 17.2% from 2022-28. As per the World Health Organization, the frequency of dengue has become significantly over ongoing many years. A larger part of the cases are asymptomatic, gentle or independent, and thus the genuine number of diseases are exceptionally under-announced. One displaying gauge demonstrates 390 million dengue infection diseases each year (95% valid span 284-528 million), of which 96 million show clinically. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, dengue vaccines market report covers newer product introductions and competition analysis with vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the dengue vaccine market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of dengue vaccine.

Key Market Developments:

In May 2019, The Food and Drug Administration approved the first vaccine against dengue fever with major restrictions.

In May 2021, Takeda’s released Phase 3 results of Dengue Vaccine Candidate (TAK-003), which Prevented 83.6% of Hospitalizations and 62.0% of Dengue Illness Overall, With No Identified Important Safety Risks Through Three Years Following Vaccination in Ongoing Pivotal TIDES Trial.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+